Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare’s PET project

This article was originally published in The Gray Sheet

Executive Summary

CMS seeks comments on alternatives to its "indication-by-indication" approach to determining whether positron emission tomography scans for cancer are reasonable and necessary. The Oct. 14 solicitation responds to extensive criticism by stakeholders. Despite an April 2004 deadline, CMS is still evaluating evidence for granting national coverage to brain, testicular, small-cell lung, cervical and pancreatic cancers (1"The Gray Sheet" Sept. 13, 2004, p. 4)...

You may also be interested in...

PET Groups Carp On CMS Coverage Policy, National Coverage Decision Delay

CMS' cautious approach to covering positron emission tomography indications has spurred criticism among the PET industry, which seeks to accelerate reimbursement to drive the technology's adoption

COVID-19: ResMed Ramps Up CPAP, BPAP Manufacturing To Address Ventilator Shortage

ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage. 

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts